AZ Closer To Second Enhertu OK After Gastric Cancer Success
Improved Overall Survival Compared With Chemo
Executive Summary
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
You may also be interested in...
Enhertu Is First ADC Approved For Tumor-Agnostic Indication
The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.
ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.